Estimation of post-operative forced expiratory volume by functional respiratory imaging

Janssens, Annelies; Vos, Wim; Holsbeke, Cedric Van; Schil, Paul Van; Oostveen, Ellie; Backer, Jan De; Carp, Laurens; Snoeckx, Annemie; Backer, Wilfried De; Meerbeeck, Jan P. van

doi:10.1183/09031936.00168314

Cited by 3 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FRI can generate functional data about airflow and drug deposition throughout the lobes of the lung. Previous FRI studies have assessed local and/or whole lung changes in airway volume and resistance in various settings, including after non-invasive or intrapulmonary percussive ventilation in patients with COPD; after surgical lung resection in patients with lung cancer; after receiving inhaled corticosteroid/long-acting β 2 -agonist (ICS/LABA) fixed-dose combination (FDC) treatment in patients with asthma; and after receiving treatment with short-acting bronchodilators, roflumilast plus ICS/long-acting muscarinic antagonist (LAMA)/LABA, mucolytics, or ICS/LABA FDCs in patients with COPD 1–10…”

Section: Introductionmentioning

confidence: 99%

A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD

Backer¹,

Backer²,

Vos³

et al. 2018

COPD

Self Cite

View full text Add to dashboard Cite

BackgroundFunctional respiratory imaging (FRI) uses high-resolution computed tomography (HRCT) scans to assess changes in airway volume and resistance.Patients and methodsIn this randomized, double-blind, 2-week, crossover, Phase IIIB study, patients with moderate-to-severe COPD received twice-daily glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler (GFF MDI, 18/9.6 μg) and placebo MDI, formulated using innovative co-suspension delivery technology. Co-primary endpoints included the following: specific image-based airway volume (siVaw) and specific image-based airway resistance (siRaw) at Day 15, measured using FRI. Secondary and other endpoints included the following: change from baseline in post-dose forced expiratory volume in 1 second (FEV1) and inspiratory capacity (IC; spirometry) and ratio to baseline in post-dose functional residual capacity (FRC) and residual volume (RV; body plethysmography).ResultsTwenty patients (46–78 years of age) were randomized and treated; of whom 19 completed the study. GFF MDI treatment increased siVaw by 75% and reduced siRaw by 71% vs placebo MDI (both P<0.0001). Image-based airway volume (iVaw) and image-based airway resistance (iRaw), without adjusting for lobe volume, demonstrated corresponding findings to the co-primary endpoint, as lobe volumes did not change with either treatment. Approximately 48% of the delivered dose of glycopyrronium and formoterol fumarate was estimated to be deposited in the lungs. Compared with placebo, GFF MDI treatment improved post-dose FEV1 and IC (443 mL and 454 mL, respectively; both P<0.001) and reduced FRC and RV (13% and 22%, respectively; both P<0.0001). There were no significant safety findings.ConclusionGFF MDI demonstrated significant, clinically meaningful benefits on FRI-based airway volume and resistance in patients with moderate-to-severe COPD. Benefits were associated with improvements in FEV1, IC, and hyperinflation.Clinical trial registrationClinicalTrials.gov: NCT02643082.

show abstract

Section: Introductionmentioning

confidence: 99%

A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD

Backer¹,

Backer²,

Vos³

et al. 2018

COPD

Self Cite

View full text Add to dashboard Cite

show abstract

Functional respiratory imaging of the airways in the acute respiratory distress syndrome

Schepens

Holsbeke

et al. 2020

Anaesthesia Critical Care & Pain Medicine

View full text Add to dashboard Cite

Functional respiratory imaging (FRI) for optimizing therapy development and patient care

Hajian

Backer

Vos

et al. 2016

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Functional imaging techniques offer the possibility of improved visualization of anatomical structures such as; airways, lobe volumes and blood vessels. Computer-based flow simulations with a three-dimensional element add functionality to the images. By providing valuable detailed information about airway geometry, internal airflow distribution and inhalation profile, functional respiratory imaging can be of use routinely in the clinic. Three dimensional visualization allows for highly detailed follow-up in terms of disease progression or in assessing effects of interventions. Here, we explore the usefulness of functional respiratory imaging in different respiratory diseases. In patients with asthma and COPD, functional respiratory imaging has been used for phenotyping these patients, to predict the responder and non-responder phenotype and to evaluate different innovative therapeutic interventions.

show abstract

Estimation of post-operative forced expiratory volume by functional respiratory imaging

Cited by 3 publications

References 15 publications

A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD

A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD

Functional respiratory imaging of the airways in the acute respiratory distress syndrome

Functional respiratory imaging (FRI) for optimizing therapy development and patient care

Contact Info

Product

Resources

About